Doxorubicin in advanced breast cancer: Influence of schedule on response, survival and quality of life

European Journal of Cancer

Volumn 28, Issue 6-7, 1992, Pages 1023-1028

  Richards, M A ^a   Hopwood, P ^b   Ramirez, A J ^a   Twelves, C J ^a   Ferguson, J ^b   Gregory, W M ^a   Swindell, R ^b   Scrivener, W ^a   Miller, J ^b   Howell, A ^b   Rubens, R D ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; STOMATITIS; SURVIVAL;

ADULT; AGED; BREAST NEOPLASMS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; MIDDLE AGE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0026750505     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(92)90447-A     Document Type: Article

References (27)

1. Combination chemotherapy and adriamycin in patients with advanced breast cancer. A southwest oncology group study
2. Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer
3. Doxorubicin: Effect of different schedules on toxicity and antitumour efficacy
4. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma
5. Average relative dose intensity and the impact on design of clinical trials
6. A phase I–II study of intensive dose adriamycin for advanced breast cancer
7. High dose induction chemotherapy of metastatic breast cancer in protected enviroment: a prospective randomised study
8. Evaluation of highdose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomised study
9. The use of granulocyte colony stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer
10. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity
11. Measurement of quality of life in patients with cancer
12. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Check List
13. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer
14. Reporting results of cancer treatment
15. Assessment of response to therapy in advanced breast cancer
16. Nonparametric Estimation from Incomplete Observations
17. Adriamycin: comparison of a 5-week schedule with a 3-week schedule in the treatment of breast cancer
18. Low versus high dose adriamycin therapy of metastatic breast cancer
19. A controlled study in the use of combined drug therapy for metastatic breast cancer
20. A comparison of subjective responses in the trial comparing endocrine and cytotoxic treatment in advanced carcinoma of the breast
21. Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer
22. Treatment and survival in advanced breast cancer
23. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule
24. Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast.
25. Comparison of shortterm and continuous chemotherapy (mitozantrone) for advanced breast cancer
26. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies
27. Combination chemoimmunotherapy of metastatic breast cancer with 5-Fluorouracil, Adriamycin, Cyclophosphamide and BCG